Nuo Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQB
Nuo Therapeutics reports a significant revenue increase in Q1 2026 driven by product sales and distribution fees, though the company continues to face substantial doubt regarding its ability to continue as a going concern.
OQB
Nuo Therapeutics reported a significant increase in Q3 2025 revenue driven by product sales and a new distribution agreement with Smith+Nephew, yet continues to face substantial doubt about its ability to continue as a going concern.
OQB
10-Q: Nuo Therapeutics Boosts Revenue with Smith & Nephew Deal, Raises Capital Amidst Going Concern Doubts
Nuo Therapeutics reported significant revenue growth driven by a new distribution agreement with Smith & Nephew and an interim sales agency, while also completing a private placement to address liquidity concerns and ongoing losses.
OQB
Nuo Therapeutics saw revenue growth in Q1 2025 and entered a distribution agreement with Smith+Nephew, but faces going concern challenges.
OQB
Nuo Therapeutics saw a significant increase in product revenue in Q3 2024 compared to Q3 2023, but continues to operate with a substantial accumulated deficit and going concern uncertainty.
OQB
10-Q: Nuo Therapeutics Reports Increased Revenue in Second Quarter 2024, Faces Going Concern Uncertainty
Nuo Therapeutics saw a significant increase in product revenue in the second quarter of 2024 compared to 2023, but continues to face challenges regarding its ability to continue as a going concern.
OQB
10-Q: Nuo Therapeutics Reports Increased Revenue in First Quarter 2024, Faces Going Concern Uncertainty
Nuo Therapeutics saw a significant increase in product revenue in Q1 2024 compared to Q1 2023, but continues to face challenges related to profitability and liquidity.